Streetbeat News

Stock Prices

MLNK

MeridianLink (NYSE:MLNK) reported Q2 2024 earnings per share of $0.04, missing the analyst estimate of $0.08. However, the company beat sales estimates with $78.676 million, a 4.32% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:21 pm

OSS

One Stop Systems shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:21 pm

GDOT

Green Dot Corporation (GDOT) has raised its FY24 guidance range for adjusted operating revenues from $1.55 billion - $1.60 billion to $1.60 billion - $1.70 billion, surpassing the estimated $1.641 billion.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

GPCR

Structure Therapeutics (NASDAQ:GPCR) reported a Q2 EPS loss of $(0.18), beating the analyst consensus estimate of $(0.23) by 21.74%. This represents a 10% improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

MNTK

Montauk Renewables has projected its FY24 revenue from renewable natural gas (RNG) to be between $195 million and $215 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

SNES

SenesTech (NASDAQ:SNES) reported Q2 2024 GAAP EPS of $(3.08), beating the estimate of $(3.20). However, sales of $459,000 missed the $485,000 estimate. Sales increased by 50.49% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

WOW

WOW! has released its Q3 2024 revenue guidance, projecting between $157 million and $160 million, slightly below the $159 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

GEOS

Geospace Technologies (NASDAQ:GEOS) reported a significant decline in its Q3 earnings and sales. The company posted a loss of $(0.16) per share, a 166.67% decrease from $0.24 per share in the same period last year. Sales also fell by 20.96% to $25.86 million from $32.72 million year-over-year.

Portfolio Pulse from totan@benzinga.com

August 08, 2024 | 9:20 pm

CHRS

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:20 pm

INAB

IN8bio (NASDAQ:INAB) reported Q2 losses of $(0.19) per share, missing the analyst consensus estimate of $(0.17) by 11.76%. This is an improvement from the $(0.27) per share loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:19 pm